Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release In the News Image Library Awards & Recognitions
  1. May 11, 2021

    Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

    CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands -  May 11, 2021   Harbour BioMed (“HBM”, HKEX: ...

    View more
  2. April 13, 2021

    Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

    CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands -  April 13, 2021    Harbour BioMed ("HBM"; ...

    View more
  3. March 30, 2021

    Harbour BioMed Reports Full Year 2020 Financial Results and Provides Corporate Update

    CAMBRIDGE, Mass., SUZHOU, China, Rotterdam, Netherlands - March 30, 2021   HBM Holdings Limited (“Harbour BioMed”, “HBM” or ...

    View more
  4. March 23, 2021

    Harbour BioMed Appoints Mai-Jing Liao, PhD, as Chief Commercial Officer

    Since its establishment, Harbour BioMed (HBM) continues to grow leaps and bounds with its innovative technology and differentiated R&D pipeline that keeps ...

    View more
  5. March 22, 2021

    Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

    Cambridge, MA, Rotterdam, NL, Shanghai, CN, Suzhou, CN – March 22, 2021   Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the...

    View more
  6. March 12, 2021

    Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial

    Cambridge, MA, Rotterdam, NL, Shanghai, CN, Suzhou, CN – March 12, 2021   Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the...

    View more
  7. February 26, 2021

    Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – February 26, 2021.   Harbour BioMed (HBM) (HKEX:02142) today announced that the China National...

    View more
  8. January 28, 2021

    Harbour BioMed’s Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— January 28, 2021.   Harbour BioMed (HBM) (HKEX: 02142.HK) announced today that China Center for...

    View more
  9. December 17, 2020

    Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange

    CAMBRIDGE, Mass., SUZHOU, China, December 17, 2020 – HBM Holdings Limited (“Harbour BioMed”, “HBM” or the "Company”; S...

    View more
  10. December 15, 2020

    Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials

    CAMBRIDGE, Mass., SUZHOU, China, UTRECHT, The Netherlands, December 14, 2020 – Harbour BioMed (HBM)(HKEX:02142) and Utrecht University (UU) today announc...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG